A systematic review of the effectiveness of adalimumab

128
References
22. Scott D, Shipley M, Dawson A, Edwards S,
Symmons D, Woolf A. The clinical management of
rheumatoid arthritis and osteoarthritis: strategies
for improving clinical effectiveness. Br J Rheumatol
1998;37:546–54.
23. Scottish Intercollegiate Guidelines Network
(SIGN). Management of early rheumatoid
arthritis. URL: http://www.sign.ac.uk/guidelines/
fulltext/48/index.html. Accessed 17 May 2005.
24. Jones G, Halbert J, Crotty M, Shanahan EM,
Batterham M, Ahern M. The effect of treatment on
radiological progression in rheumatoid arthritis: a
systematic review of randomized placebo-controlled
trials. Rheumatology 2003;42:6–13.
25. Jobanputra P, Wilson J, Douglas K, Burls A.
A survey of British rheumatologists’ DMARD
preferences for rheumatoid arthritis. Rheumatology
2004;43:206–10.
26. Pincus T, Marcum SB, Callahan LF. Long-term
drug therapy for rheumatoid arthritis in seven
rheumatology private practices: II. Second line
drugs and prednisone. J Rheumatol 1992;
19:1885–94.
27. Hickling P, Jacoby RK, Kirwan JR. Arthritis and
Rheumatism Council Low Dose Glucocorticoid
Study Group. Joint destruction after
glucocorticoids are withdrawn in early rheumatoid
arthritis. Rheumatology 1998;37:930–6.
28. Boers M, Verhoeven AC, Markusse HM, van de
Laar MAFJ, Westhovens R, van Denderen JC, et al.
Randomised comparison of combined step-down
prednisolone, methotrexate and sulphasalazine
with sulphasalazine alone in early rheumatoid
arthritis. Lancet 1997;350:309–18.
29. Choy EC, Kingsley GH, Khoshaba B, Pipitone N,
Scott DL, Intramuscular Methyprednisolone Study
Group. A two year randomised controlled trial of
intramuscular depot steroids in patients with
established rheumatoid arthritis who have shown a
complete response to disease modifying
antirheumatic drugs. Ann Rheum Dis 2005;
64:1288–93.
30. Choi H, Hernan M, Seeger J, Wolfe F.
Methotrexate and mortality in patients with
rheumatoid arthritis. Lancet 2002;359:1173–7.
31. Blue Cross & Blue Shield Association. Special
Report: Evidence on sequencing of conventional
and biological disease-modifying anti-rheumatic
drugs. URL: http://www.bcbs.com/tec/
vol118/18_11.html. Accessed 18 May 2005.
32. Landewe RBM. The benefits of early treatment in
rheumatoid arthritis. Arthritis Rheum 2003;48:1–5.
33. Visser H, Le Cessie S, Vos K, Breedveld FC,
Hazes JMW. How to diagnose rheumatoid arthritis
early. A prediction model for persistent (erosive)
arthritis. Arthritis Rheum 2002;46:357–65.
34. Edwards CJ, Arden NK, van Staa TP, Reading I,
Saperia JC, Fisher D, et al. The changing use of
disease-modifying anti-rheumatic drugs in
individuals with RA from the General Practice
Research Database (GPRD). Rheumatology 2005;
44(Suppl 1):i2.
35. Jobanputra P, Homer D, Maggs F, Beavan J.
Serious adverse events to disease modifying antirheumatic
drugs for inflammatory arthritis: a West
Midlands experience. Drug Saf 2002;25:1099–105.
36. Felson D, Anderson J, Meenan R. Use of shortterm
efficacy/toxicity tradeoffs to select second-line
drugs in rheumatoid arthritis. A meta-analysis of
published clinical trials. Arthritis Rheum 1992;
35:1117–25.
37. Mottonen T, Hannonen P, Leirisalo-Repo M,
Nissila M, Kautiainen H, Korpela M. Comparison
of combination therapy with single-drug therapy
in early rheumatoid arthritis: a randomised trial.
Lancet 1999;353:1568–73.
38. Sokka T, Mottonen T, Hannonen P. Diseasemodifying
anti-rheumatic drug use according to
the ‘sawtooth’ treatment strategy improves the
functional outcome in rheumatoid arthritis: results
of a long-term follow-up study with review of the
literature. Rheumatology 2000;39:34–42.
39. Viller F, Guillemin F, Briancon S, Moum T,
Suurmeijer T, van den Heuvel W. Compliance with
drug therapy in rheumatoid arthritis: a
longitudinal European study. Joint Bone Spine
2000;67:178–82.
40. Wolfe F, Zwillich SH. The long-term outcomes of
rheumatoid arthritis. Arthritis Rheum 1998;
41:1072–82.
41. van Gestel AM, Haagsma CJ, Van Riel PLCM.
Validation of rheumatoid arthritis improvement
criteria that include simplified joint counts.
Arthritis Rheum 1998;41:1845–50.
42. Fransen J, Creemers MCW, Van Riel PLCM.
Remission in rheumatoid arthritis: agreement of
the disease activity score (DAS28) with the ARA
preliminary remission criteria. Rheumatology 2004;
43:1252–5.
43. van Gestel AM, Prevoo MLL, van ‘T Hof MA, van
Rijswijk MH, Van De Putte LBA, Van Riel PLCM.
Development and validation of the European
League Against Rheumatism response criteria for
rheumatoid arthritis. Comparison with the
Preliminary American College of Rheumatology
and the World Health Organisation/International
League Against Rheumatism criteria. Arthritis
Rheum 1996;39:34–40.
44. Kirwan JR. Links between radiological change,
disability and pathology in rheumatoid arthritis.
Rheumatology 2001;40:881–6.
45. Landewe R, Boers M, van der Heijde D. How to
interpret radiological progression in randomised
clinical trials? Rheumatology 2003;42:2–5.